OBJECTIVES: To determine the HIV genetic subtypes present in HIV-1-infected asymptomatic blood donors in Uganda and to evaluate serologic detection of infection by commercial immunoassays; to evaluate samples for HIV-1 group O infections. METHODS: Sixty-four HIV-seropositive plasma samples were collected from the Nakasero Blood Bank, Kampala, Uganda. The plasma were evaluated using commercial HIV enzyme immunoassays (EIA) and a research immunoblot. HIV-1 group M and O infections were identified on the basis of discordant seroreactivity in EIA and reactivity to group M and O antigens on the immunoblot. Regions of gag p24 and env gp41 were amplified using reverse transcriptase polymerase chain reaction, and genetic subtypes were determined by phylogenetic analysis. RESULTS: Serologic testing confirmed that 63 out of 64 plasma units were positive for HIV-1 group M infection and showed no evidence of HIV-1 group O infections. Genetic subtyping determined that 25 samples were subtype A, three subtype C, 22 subtype D, and nine were heterogeneous for subtypes A and D. CONCLUSIONS: Despite the sequence variation observed in Uganda, commercial EIA based on HIV-1 subtype B proteins detected all the infections. In contrast, a peptide-based assay failed to detect three infections by subtype D viruses. This emphasizes the negative impact of HIV genetic variation on assays that rely on peptides to detect HIV infections. The number of infections with heterogeneous subtype (due to mixed infections or recombinant viruses) is high and reflects the growing complexity of the HIV epidemic in endemic regions where multiple subtypes are present in the population.
OBJECTIVES: To determine the HIV genetic subtypes present in HIV-1-infected asymptomatic blood donors in Uganda and to evaluate serologic detection of infection by commercial immunoassays; to evaluate samples for HIV-1 group Oinfections. METHODS: Sixty-four HIV-seropositive plasma samples were collected from the Nakasero Blood Bank, Kampala, Uganda. The plasma were evaluated using commercial HIV enzyme immunoassays (EIA) and a research immunoblot. HIV-1 group M and O infections were identified on the basis of discordant seroreactivity in EIA and reactivity to group M and O antigens on the immunoblot. Regions of gagp24 and env gp41 were amplified using reverse transcriptase polymerase chain reaction, and genetic subtypes were determined by phylogenetic analysis. RESULTS: Serologic testing confirmed that 63 out of 64 plasma units were positive for HIV-1 group M infection and showed no evidence of HIV-1 group Oinfections. Genetic subtyping determined that 25 samples were subtype A, three subtype C, 22 subtype D, and nine were heterogeneous for subtypes A and D. CONCLUSIONS: Despite the sequence variation observed in Uganda, commercial EIA based on HIV-1 subtype B proteins detected all the infections. In contrast, a peptide-based assay failed to detect three infections by subtype D viruses. This emphasizes the negative impact of HIV genetic variation on assays that rely on peptides to detect HIV infections. The number of infections with heterogeneous subtype (due to mixed infections or recombinant viruses) is high and reflects the growing complexity of the HIV epidemic in endemic regions where multiple subtypes are present in the population.
Entities:
Keywords:
Africa; Africa South Of The Sahara; Demographic Factors; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Examinations And Diagnoses; Hiv; Hiv Infections; Hiv Serodiagnosis; Laboratory Examinations And Diagnoses; Population; Population Characteristics; Research Report; Uganda; Urban Population; Viral Diseases
Authors: M Mracna; G Becker-Pergola; J Dileanis; L A Guay; S Cunningham; J B Jackson; S H Eshleman Journal: J Clin Microbiol Date: 2001-12 Impact factor: 5.948
Authors: T D Ly; L Martin; D Daghfal; A Sandridge; D West; R Bristow; L Chalouas; X Qiu; S C Lou; J C Hunt; G Schochetman; S G Devare Journal: J Clin Microbiol Date: 2001-09 Impact factor: 5.948
Authors: Najah I Doka; Shevin T Jacob; Patrick Banura; Christopher C Moore; David Meya; Harriet Mayanja-Kizza; Steven J Reynolds; W Michael Scheld; Wen Yuan Journal: PLoS One Date: 2012-10-29 Impact factor: 3.240
Authors: D J Hu; J Baggs; R G Downing; D Pieniazek; J Dorn; C Fridlund; B Biryahwaho; S D Sempala; M A Rayfield; T J Dondero; R Lal Journal: Emerg Infect Dis Date: 2000 Nov-Dec Impact factor: 6.883
Authors: Alisen Ayitewala; Fred Kyeyune; Pamela Ainembabazi; Eva Nabulime; Charles Drago Kato; Immaculate Nankya Journal: AIDS Res Ther Date: 2020-01-31 Impact factor: 2.250